Cancer Family
B-Cell Malignant Neoplasm
CI-CAN-00000070Explore in graph →
Hematologic2,083 active trials46 approved drugs301 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000070Explore in graph →
Clinical trials
7,465 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,167)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00425347 | Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 in Subjects With Advanced Multiple Myeloma | completed | Phase 1 | 35 | Facet BiotechINDUSTRY | 1 | Sep 23, 2009 | clinicaltrials |
| NCT00391157 | VELCADEXA: Velcade and Dexamethasone in Multiple Myeloma | completed | Phase 2 | 40 | PETHEMA FoundationOTHER | 1 | Sep 18, 2009 | clinicaltrials |
| NCT00461747 |
| GEM05 for Patients With Multiple Myeloma Under 65 Years(GEM05MENOS65) |
| completed |
| Phase 3 |
| 390 |
| PETHEMA FoundationOTHER |
| 1 |
| Sep 18, 2009 |
| clinicaltrials |
| NCT00965289 | High-dose Chemotherapy With Rituximab for Adults With Aggressive Large B-cell Lymphoma | completed | Phase 2 | 42 | Nantes University HospitalOTHER | 1 | Aug 26, 2009 | clinicaltrials |
| NCT00186316 | Vaccine Therapy for Multiple Myeloma Utilizing Idiotype-Pulsed Allogeneic Dendritic Cells | completed | Phase 1 / Phase 2 | 30 | Stanford UniversityOTHER | 1 | Aug 25, 2009 | clinicaltrials |
| NCT00327249 | Safety and Efficacy Study of Imexon for Treatment of Multiple Myeloma Patients | completed | Phase 1 / Phase 2 | — | AmpliMed CorporationINDUSTRY | 1 | Aug 11, 2009 | clinicaltrials |
| NCT00306813 | Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 53 | University of WuerzburgOTHER | 1 | Aug 4, 2009 | clinicaltrials |
| NCT00950768 | Melphalan 200 mg/m2 Versus Melphalan 100 mg/m2 in Newly Diagnosed Myeloma Patients | completed | Phase 3 | 298 | Azienda Ospedaliera San Giovanni BattistaOTHER | 0 | Aug 3, 2009 | clinicaltrials |
| NCT00210327 | VELCADE in MALT Lymphoma Pretreated With Prior Systemic Therapy | completed | Phase 2 | 33 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 1 | Jul 22, 2009 | clinicaltrials |
| NCT00210379 | Phase II Study of Combined Modality Treatment in Primary Testicular Non-Hodgkin's Lymphoma | completed | Phase 2 | 64 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 1 | Jul 22, 2009 | clinicaltrials |
| NCT00436059 | The Efficacy of Velcade on Bone Tissue During Myelomatosis (Bone Marrow Cancer) | completed | Phase 2 | 20 | Vejle HospitalOTHER | 1 | Jul 8, 2009 | clinicaltrials |
| NCT00373646 | Thalidomide in Mucosa Associated Lymphoid Tissue (MALT) Lymphoma Patients | completed | Phase 2 | 8 | Medical University of ViennaOTHER | 1 | Jun 18, 2009 | clinicaltrials |
| NCT00910078 | Serum Free Light Change in Multiple Myeloma | completed | — | — | Azienda Ospedaliera San Giovanni BattistaOTHER | 1 | May 29, 2009 | clinicaltrials |
| NCT00781170 | Dose-Reduced Allogeneic Stem Cell Transplantation After Autologous High-Dose Chemotherapy in Patients With Multiple Myeloma | completed | Phase 2 | 20 | Universitätsklinikum Hamburg-EppendorfOTHER | 0 | May 28, 2009 | clinicaltrials |
| NCT00036023 | Chemotherapy Related Anemia in Patients With Non-Myeloid Malignancies | completed | Phase 2 | — | AmgenINDUSTRY | 0 | May 11, 2009 | clinicaltrials |
| NCT00080405 | Repeat-Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients With Relapsed Multiple Myeloma | completed | Phase 1 | 40 | Millennium Pharmaceuticals, Inc.INDUSTRY | 0 | Mar 27, 2009 | clinicaltrials |
| NCT00111319 | VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previously Untreated Multiple Myeloma | completed | Phase 3 | — | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 26, 2009 | clinicaltrials |
| NCT00859001 | Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) Study in Patients With Follicular Grade I-II Lymphoma After 4 Cycles of Fludarabine-Mitoxantrone-Rituximab (FMR) Therapy(FM+R-Z) | completed | Phase 2 | 55 | University of BolognaOTHER | 1 | Mar 12, 2009 | clinicaltrials |
| NCT00592579 | A Phase 2 Study With Panzem in Patients With Relapsed or Plateau Phase Multiple Myeloma | completed | Phase 2 | 60 | CASI pharmaceuticals, Inc.INDUSTRY | 1 | Feb 26, 2009 | clinicaltrials |
| NCT00850512 | Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) in Elderly (More Than 60 Years) Patients With Diffuse Large B Cell Lymphoma After 4 Cycles of CHOP21-Rituximab (CHOP21-R) Therapy(CHOP21+R-Z) | completed | Phase 2 | 55 | University of BolognaOTHER | 1 | Feb 25, 2009 | clinicaltrials |
| NCT00285389 | Treatment of Mantle Cell Lymphoma at Diagnosis for Patients Under 65 Years | completed | Phase 2 | 39 | French Innovative Leukemia OrganisationOTHER | 1 | Feb 12, 2009 | clinicaltrials |
| NCT00200681 | IFM 2005-01: Velcade/Dexamethasone Versus Vincristine/Adriamycin (Doxorubicin)/Dexamethasone (VAD) for the Treatment of Patients With Multiple Myeloma | completed | Phase 3 | 493 | Nantes University HospitalOTHER | 1 | Feb 5, 2009 | clinicaltrials |
| NCT00291538 | Comparison of Pharmacokinetics and Pharmacodynamics of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma | completed | Phase 1 | 20 | Nantes University HospitalOTHER | 1 | Feb 4, 2009 | clinicaltrials |
| NCT00207805 | The Optimal Timing of a Second Autologous Peripheral Blood Stem Cell Transplantation in Patients (<61 Years) With Multiple Myeloma | completed | Phase 3 | 202 | Centre National de Greffe de Moelle OsseuseOTHER_GOV | 1 | Jan 27, 2009 | clinicaltrials |
| NCT00516152 | Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT | completed | Phase 2 | 36 | University of California, San FranciscoOTHER | 1 | Jan 26, 2009 | clinicaltrials |
| NCT00193544 | Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple Myeloma | completed | Phase 2 | 40 | SCRI Development Innovations, LLCOTHER | 0 | Jan 23, 2009 | clinicaltrials |
| NCT00579917 | Behavioral Intervention For BMT/SCT Survivors(BMT/SCT) | completed | — | 133 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 7, 2009 | clinicaltrials |
| NCT00560053 | Pethema Multiple Myeloma 2000 | completed | Phase 3 | 500 | PETHEMA FoundationOTHER | 0 | Nov 27, 2008 | clinicaltrials |
| NCT00783588 | A Phase I Extension Trial of Repeated Infusions of ISF35 | completed | Phase 1 | 4 | Memgen, LLCINDUSTRY | 1 | Oct 31, 2008 | clinicaltrials |
| NCT00316511 | Study of L-NDDP (Aroplatin) in Patients With Advanced Solid Malignancies or B-Cell Lymphoma | completed | Phase 1 | 21 | Agenus Inc.INDUSTRY | 1 | Oct 27, 2008 | clinicaltrials |
| NCT00696735 | High-Dose Therapy Treatment in Patients With Follicular Lymphoma | completed | Phase 3 | 172 | French Innovative Leukemia OrganisationOTHER | 1 | Oct 24, 2008 | clinicaltrials |
| NCT00779883 | A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35) | completed | Phase 1 | 9 | Memgen, LLCINDUSTRY | 1 | Oct 24, 2008 | clinicaltrials |
| NCT00204659 | Phase II Study With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With Gastric Diffuse Large B-Cell Non-Hodgkin's Lymphoma | completed | Phase 2 | 30 | University Hospital TuebingenOTHER | 1 | Oct 20, 2008 | clinicaltrials |
| NCT00290004 | Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 1 / Phase 2 | 35 | Pharmacyclics LLC.INDUSTRY | 1 | Sep 11, 2008 | clinicaltrials |
| NCT00017680 | Study of High-Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Primary Light Chain Amyloidosis | completed | Phase 2 | 25 | Herbert Irving Comprehensive Cancer CenterOTHER | 1 | Jun 9, 2008 | clinicaltrials |
| NCT00113204 | Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma(IPi-504-01) | completed | Phase 1 | 18 | Infinity Pharmaceuticals, Inc.INDUSTRY | 1 | May 20, 2008 | clinicaltrials |
| NCT00320476 | VTD Followed By MPT Maintenance As a First Line Treatment For The Patients With MM Who Are Non-Transplant Candidates | completed | Phase 2 | 35 | Korean Multiple Myeloma Working PartyOTHER | 1 | May 6, 2008 | clinicaltrials |
| NCT00633542 | Maintenance Therapy After Thalidomide-Dexamethasone(ThaDD) for Multiple Myeloma(MM) | completed | Phase 3 | 103 | Università Politecnica delle MarcheOTHER | 1 | Mar 12, 2008 | clinicaltrials |
| NCT00001237 | Pilot Protocol for the Treatment of Patients With Small Non-Cleaved and Diffuse Large Cell Lymphomas | completed | Phase 2 | 120 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00001271 | A Phase I Study of Continuous Infusion Immunotoxin IgG-RFB4-SMPT-dgA in Refractory CD22 Positive B-Cell Lymphoma | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00001567 | A Phase II Efficacy Study of Roferon-A in Hairy Cell Leukemia | completed | Phase 2 | 56 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00001750 | Comparing Treatments for Multiple Myeloma | completed | Phase 2 | 32 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00063713 | VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma | completed | Phase 2 | 152 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 11, 2008 | clinicaltrials |
| NCT00085696 | VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma | completed | Phase 2 | 66 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 11, 2008 | clinicaltrials |
| NCT00257114 | Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability | completed | Phase 4 | — | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 11, 2008 | clinicaltrials |
| NCT00090090 | Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma | completed | Phase 2 | 114 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Jan 15, 2008 | clinicaltrials |
| NCT00116441 | Vaccination in the Peripheral Stem Cell Transplant Setting for Multiple Myeloma | completed | Phase 1 / Phase 2 | 22 | Cell GenesysINDUSTRY | 1 | Dec 24, 2007 | clinicaltrials |
| NCT00086216 | Safety and Efficacy of Atiprimod for Patients With Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 30 | Callisto PharmaceuticalsINDUSTRY | 1 | Dec 21, 2007 | clinicaltrials |
| NCT00165347 | Protein Tyrosine Kinases (PTK) in Multiple Myeloma | completed | Phase 2 | 10 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 21, 2007 | clinicaltrials |
| NCT00558220 | R-MegaCHOP-ESHAP-BEAM in Patients With High-Risk Aggressive B-Cell Lymphomas(R-MCEB) | completed | Phase 2 | 106 | Czech Lymphoma Study GroupOTHER | 1 | Nov 14, 2007 | clinicaltrials |
Data updated 22 days agoSource updated Sep 23, 2009source: clinicaltrials